SANTA CRUZ BIOTECHNOLOGY, INC.

GIP (6F106): sc-71148

BACKGROUND

Glucose-dependent Insulinotropic polypeptide (GIP) is a major physiologic factor in the augmentation of the Insulin response to oral glucose. GIP is a peptide hormone that is released postprandially from the small intestine and acts in concert with glucagon-like peptide (GLP)-1 to potentiate glucose-induced Insulin secretion from the pancreatic β-cell. GIP has been shown to increase adenylyl cyclase activity, elevate intracellular calcium levels, and stimulate a mitogen-activated protein kinase pathway in the pancreatic β-cell. Additionally, nutrient protein provides a potent stimulus for GIP expression, an effect that occurs at the posttranslational level and may be mediated in part through the acid-stimulatory properties of protein. GIP release is demonstrated predominantly after ingestion of carbohydrate and fat and the effects of acid on GIP are consistent with a role for GIP as an enterogastrone.

REFERENCES

1. Sarson, D.L., et. al. 1984. Glucose-dependent Insulinotropic polypeptide augmentation of Insulin. Physiology or pharmacology? Diabetes 33: 389-393.

2. Meneilly, G.S., et. al. 2000. Effect of ageing and diabetes on glucose-dependent Insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet. Med. 17: 346-350.

3. Lynn, F.C., et. al. 2001. Defective glucose-dependent Insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50: 1004-1011.

4. Ehses, J.A., et. al. 2001. A new pathway for glucose-dependent Insulinotropic polypeptide (GIP) receptor signaling. evidence for the involvement of phospholipase $\alpha2$ in GIP-stimulated Insulin secretion. J. Biol. Chem. 276: 23667-13673.

5. Wolfe, M.M., et. al. 2000. Regulation of glucose-dependent Insulinotropic polypeptide release by protein in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G561-G566.

6. Irwin, N., et. al. 2006. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent Insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Regul. Pept. 135: 45-53.

7. Parker, J.C., et. al. 2006. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent Insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on Insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol. 191: 93-100.

8. Kim, S.J., et. al. 2007. Activation of lipoprotein lipase (LPL) by glucose-dependent Insulinotropic polypeptide (GIP) in adipocytes: A role for a protein kinase B (PKB), LKB1 and AMP-activated protein kinase (AMPK) cascade. J. Biol. Chem. 282: 8557-8567.

9. Irwin, N., et. al. 2007. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Diabetes Metab. Res. Rev. 23: 572-579.

CHROMOSOMAL LOCATION

Genetic locus: GIP (human) mapping to 17q21.32.

SOURCE

GIP (6F106) is a mouse monoclonal antibody raised against synthetic GIP of human origin.

PRODUCT

Each vial contains 200 µg IgG$_1$ in 1.0 mL PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

GIP (6F106) is recommended for detection of GIP of human origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for GIP siRNA (h): sc-72038, GIP shRNA Plasmid (h): sc-72038-SH and GIP shRNA (h) Lentiviral Particles: sc-72038-V.

Molecular Weight of GIP: 5 kDa.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.